<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04208932</url>
  </required_header>
  <id_info>
    <org_study_id>ZH2018ZDA29</org_study_id>
    <nct_id>NCT04208932</nct_id>
  </id_info>
  <brief_title>A Kynurenine Pathway-based Molecular Imaging Study of Individualized Diagnosis and Treatment for Major Depressive Disorder</brief_title>
  <official_title>A Kynurenine Pathway-based Molecular Imaging Study of Individualized Diagnosis and Treatment for Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Mental Health Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Major depressive disorder (MDD) is a chronic disease with high incidence rate, high recurrent&#xD;
      rate and need whole course medical management. Varied clinical symptoms and unclear&#xD;
      pathogenesis cause a series of clinical problem, such as low diagnostic rate and low&#xD;
      effective treatment rate. Based on neuroimmune mechanisms of MDD, our previous study&#xD;
      indicates that kynurenine pathway (KP) in serum may be the connections between central immune&#xD;
      and peripheral immune, that key factors of KP may change the brain structure and function&#xD;
      through affecting the central immune. The core research issue of this project are the&#xD;
      inherent associations between metabonomics of inflammatory factors in KP, clinical phenotypes&#xD;
      of MDD, and neuroimaging features. This project will focus on first-episode MDD, mass&#xD;
      spectrometry analysis of KP factors will be conducted first, also multi-modal neuroimaging&#xD;
      techniques will be applied to detect topological characteristics of brain structure and&#xD;
      function in MDD and extract standard models, then correlation analyses will be performed&#xD;
      between these molecular biological features and multi-dimensional clinical data in order to&#xD;
      integrate KP metabonomics, core clinical characteristics (depressed mood, energy loss,&#xD;
      interest loss and so on), neuroimaging biomarkers, and finally construct the deep learning&#xD;
      based standard diagnostic technique of MDD. Additionally, this project will follow up MDD&#xD;
      patients with different core clinical characteristics to certificate the aforementioned&#xD;
      diagnostic technique as well as explore optimized treatment for different clinical subtypes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 12, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>remission of acute phase</measure>
    <time_frame>12th week</time_frame>
    <description>scored 7 or lower on the Hamilton's Depression Scale with 24 items</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">440</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>MDD</arm_group_label>
    <description>major depressive disorder</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HC</arm_group_label>
    <description>healthy control</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SSRIs</intervention_name>
    <description>Selective Serotonin Reuptake Inhibitors</description>
    <arm_group_label>MDD</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood sample&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        370 patients with the major depressive disorder who are first-episode drug-naive or&#xD;
        medication-free for no less than 2 weeks; 70 healthy participants&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18-60 years old;&#xD;
&#xD;
          2. Meeting with the criteria of major depressive disorder in the Diagnostic and&#xD;
             Statistical Manual of Mental Disorders (DSM)-5;&#xD;
&#xD;
          3. Scored 20 or higher on the Hamilton's Depression Scale with 24 items (HAMD-24);&#xD;
&#xD;
          4. With enough audio-visual ability and comprehensive ability to accomplish the visits;&#xD;
&#xD;
          5. Be necessary and suitable to accept the treatment of antidepressants;&#xD;
&#xD;
          6. Scored less than 14 on Hamilton's Anxiety Scale (HAMA) and scored less than 14 on the&#xD;
             Hypomania Symptom Checklist-32 (HCL-32);&#xD;
&#xD;
          7. With 2 or more atypical symptoms including significant weight gain or increase in&#xD;
             appetite, hypersomnia, leaden paralysis, and a long-standing pattern of interpersonal&#xD;
             rejection sensitivity that results in significant social or occupational impairment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Severe medical or neurological problems;&#xD;
&#xD;
          2. Previous mania or hypomania episodes;&#xD;
&#xD;
          3. Female patients who are pregnant, planning to be pregnant or breastfeeding;&#xD;
&#xD;
          4. Actively suicide ascertained by research psychiatrist or 3rd item of HAMD&#xD;
             scoredâ‰¥3(suicidality);&#xD;
&#xD;
          5. Had electroconvulsive therapy, modified electroconvulsive therapy or repetitive&#xD;
             transcranial magnetic stimulation in the past 6 months;&#xD;
&#xD;
          6. Experienced severe personality disorder, mental retardation, anorexia/bulimia nervosa.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daihui Peng, MD.PhD.</last_name>
    <role>Study Chair</role>
    <affiliation>Shanghai Mental Health Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daihui Peng, MD.PhD.</last_name>
    <phone>18017311136</phone>
    <email>pdhsh@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Mental Health Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daihui Peng, M.D.,Ph.D.</last_name>
      <phone>18017311136</phone>
      <email>pdhsh@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 20, 2019</study_first_submitted>
  <study_first_submitted_qc>December 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 23, 2019</study_first_posted>
  <last_update_submitted>December 23, 2019</last_update_submitted>
  <last_update_submitted_qc>December 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

